Abstract
Diabetes mellitus is a chronic metabolic disorder, characterized by glucose overproduction and glucose underutilization. Current therapy for T2DM includes drugs, like metformin, glitazones, sulphonyl ureas, etc. Extensive research has been carried out world wide on molecular targets for T2DM like PPARγ, PTP1B, DPP-IV, GSK-3, cannabinoid receptor, fructose-bisphosphatases, β3 adrenoceptor, etc. in the development of newer anti-diabetic agents. These therapeutic targets are quite important and most of them are suitable for in silico analysis. Hence, many molecular modeling and informatics studies like, molecular docking, pharmacophore mapping, 3DQSAR, virtual screening, quantum chemical studies, and pharmacoinformatics like bioinformatics and chemoinformatics studies have been performed on the drugs / leads / targets associated with T2DM. Several of these in silico efforts are exemplary studies; the methodologies adopted in these studies can be emulated in many other therapeutic areas. A review of the rational approaches reported in designing anti-diabetic agents is presented in this article.
Keywords: Molecular modeling, informatics, Diabetes mellitus, Dipeptidyl peptidase IV, Cannabinoid, β3-adrenoceptor, Glycogen synthase kinase-3, Protein tyrosine phosphatase-1B, Pyruvate dehydogenase kinase
Current Pharmaceutical Design
Title: Modeling and Informatics in Designing Anti-Diabetic Agents
Volume: 13 Issue: 34
Author(s): P. V. Bharatam, D. S. Patel, L. Adane, A. Mittal and S. Sundriyal
Affiliation:
Keywords: Molecular modeling, informatics, Diabetes mellitus, Dipeptidyl peptidase IV, Cannabinoid, β3-adrenoceptor, Glycogen synthase kinase-3, Protein tyrosine phosphatase-1B, Pyruvate dehydogenase kinase
Abstract: Diabetes mellitus is a chronic metabolic disorder, characterized by glucose overproduction and glucose underutilization. Current therapy for T2DM includes drugs, like metformin, glitazones, sulphonyl ureas, etc. Extensive research has been carried out world wide on molecular targets for T2DM like PPARγ, PTP1B, DPP-IV, GSK-3, cannabinoid receptor, fructose-bisphosphatases, β3 adrenoceptor, etc. in the development of newer anti-diabetic agents. These therapeutic targets are quite important and most of them are suitable for in silico analysis. Hence, many molecular modeling and informatics studies like, molecular docking, pharmacophore mapping, 3DQSAR, virtual screening, quantum chemical studies, and pharmacoinformatics like bioinformatics and chemoinformatics studies have been performed on the drugs / leads / targets associated with T2DM. Several of these in silico efforts are exemplary studies; the methodologies adopted in these studies can be emulated in many other therapeutic areas. A review of the rational approaches reported in designing anti-diabetic agents is presented in this article.
Export Options
About this article
Cite this article as:
Bharatam V. P., Patel S. D., Adane L., Mittal A. and Sundriyal S., Modeling and Informatics in Designing Anti-Diabetic Agents, Current Pharmaceutical Design 2007; 13 (34) . https://dx.doi.org/10.2174/138161207782794239
DOI https://dx.doi.org/10.2174/138161207782794239 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin E - Occurrence, Biosynthesis by Plants and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry The Changing Face of HIV/AIDS in Treated Patients
Current HIV Research Editorial (Thematic Issue: Cognitive Dysfunction in Major Depressive Disorder - Pathophysiology, Clinical Implications and Treatment Opportunities)
CNS & Neurological Disorders - Drug Targets Immediate and Late Adverse Reactions to Iodinated Contrast Media: A Pharmacological Point of View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inflammation and Mood Disorders: Proinflammatory Cytokines and the Pathogenesis of Depression
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Effect of Statin Therapy on Arterial Stiffness by Measuring Pulse Wave Velocity: A Systematic Review
Current Vascular Pharmacology A Comparison of Emotional Decoding Abilities in Patients with Amnestic Mild Cognitive Impairment, Very Mild and Mild Alzheimer’s Disease
Current Alzheimer Research A proteomics based approach for the identification of gastric cancer related markers
Current Pharmaceutical Design Apoptotic Signaling Pathways as a Target for the Treatment of Liver Diseases
Mini-Reviews in Medicinal Chemistry Amylin Conjugation with Methoxyl Polyethyleneglycol
Protein & Peptide Letters Editorial: Statin Potency, LDL Receptors and New Onset Diabetes
Current Vascular Pharmacology Islet Inflammation in Type 2 Diabetes (T2D): From Endothelial to β-Cell Dysfunction
Current Immunology Reviews (Discontinued) Autophagy Dysfunction and its Link to Alzheimer’s Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Highlights on Important Medicinal Plants for the Menopause Syndrome
Current Women`s Health Reviews Fitness or Fatness: The Debate Continues for AMP-Activated Protein Kinase in Heart Function
Current Cardiology Reviews Dietary Habits of Mongolian People, and Their Influence on Lifestyle-Related Diseases and Early Aging
Current Aging Science Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke
Current Molecular Medicine Prolonged Perfusion Predicts Recurrent Ischemic Stroke but not Transient Ischemic Attack in Patients with Symptomatic Intracranial Stenosis
Current Neurovascular Research Genomic Strategies in Pharmacology of Asthma and Autoimmunity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Clinically Significant Proteinuria Following the Administration of Sirolimus to Renal Transplant Recipients
Drug Metabolism Letters